The effectiveness of palbociclib plus regorafenib combination observed in HCC cell models was associated with a significant down-regulation of CDK4/6-Rb-myc and mTORC1/p70S6K signaling. This evidence concerns the gene CDK4 and hepatocellular carcinoma.